Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.
about
Targeted therapy for localized non-small-cell lung cancer: a reviewFrom diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert PanelPhase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).Adjuvant or neoadjuvant chemotherapy for NSCLC.The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer.Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumabPathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.The non-coding transcriptome as a dynamic regulator of cancer metastasisInduction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer.Angiogenesis Inhibitors in NSCLC.Is single-station N2 disease on PET-CT an indication for primary surgery in lung cancer patients?Before or After: Evolving Neoadjuvant Approaches to Locally Advanced Non-Small Cell Lung Cancer.Immunotherapy in surgically resectable non-small cell lung cancer.Surgical Treatment following Chemo-Targeted Therapy with Bevacizumab for Lung Metastasis from Colorectal Carcinoma: Analysis of Safety and Histological Therapeutic Effects in Patients Treated at a Single Institution.Neoadjuvant immunotherapy for non-small cell lung cancer: can early intervention result in durable clinical benefit?
P2860
Q26741441-49C83DAE-8600-4FA0-8DC9-FAD7B09BC1C4Q28066842-6B1BB4E9-380E-42A0-B6DB-E2329D11671AQ33428645-A10A161B-16EE-4F39-A64F-7A6DF2D715AAQ33658228-85B2BB10-AB65-46B4-99CC-EADD5EB12C18Q33886353-91B568DD-5540-4C63-AECF-8135EA67A517Q35592628-0A3CE805-4AF1-45B6-A4CF-5167380D057CQ36301449-3D57A265-1A9A-49B8-94AD-24447746F732Q36525431-6F9F0301-BF8E-4AEA-AFFE-69FFD532ECBAQ36557569-FA3530BC-9BB1-4CE1-9DBE-6BE04F3747E4Q36852170-7480E933-0D60-4C57-98F6-59E69CD65B64Q37705696-CC5AEC38-DC1F-4A0C-877A-EF605B8F9D22Q46090770-4705646F-B958-473B-A9F3-4C0E34F34B8FQ47095393-741A7905-17AB-4FA5-92D6-F42D04AAA1BDQ47187353-7F4EA1C5-C369-4720-A9D2-58C8C26D53FCQ49256406-867D7B9B-0265-4A59-A754-C99EF840219CQ52624364-A520C8A0-BCDF-4DF7-BE02-66CF0CDE84A8Q55346189-986BA916-4E38-415C-8CD5-B1DFCFE8433EQ58128666-F4EB4167-F79F-44B0-8747-361251B77149
P2860
Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Phase II trial of neoadjuvant ...... s non-small-cell lung cancers.
@ast
Phase II trial of neoadjuvant ...... s non-small-cell lung cancers.
@en
Phase II trial of neoadjuvant ...... s non-small-cell lung cancers.
@nl
type
label
Phase II trial of neoadjuvant ...... s non-small-cell lung cancers.
@ast
Phase II trial of neoadjuvant ...... s non-small-cell lung cancers.
@en
Phase II trial of neoadjuvant ...... s non-small-cell lung cancers.
@nl
prefLabel
Phase II trial of neoadjuvant ...... s non-small-cell lung cancers.
@ast
Phase II trial of neoadjuvant ...... s non-small-cell lung cancers.
@en
Phase II trial of neoadjuvant ...... s non-small-cell lung cancers.
@nl
P2093
P2860
P50
P921
P1476
Phase II trial of neoadjuvant ...... us non-small-cell lung cancers
@en
P2093
Camelia S Sima
Christopher G Azzoli
David J Finley
Gregory J Riely
Katharine A R Price
Lee M Krug
Manjit S Bains
Matthew G Fury
Michelle S Ginsberg
Nabil Rizk
P2860
P304
P356
10.1097/JTO.0B013E31829923EC
P577
2013-08-01T00:00:00Z